Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03952767 · ClinicalTrials.gov registry record · NA

The STEPP Study: Sensors To Evaluate Physical Performance

A NA study of Oncology, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
63
Enrollment target
1
Study location

NCT03952767: Completed NA study of Oncology, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT03952767 is a NA study of Oncology that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 63 participants, below the 525-participant average among 24 other Oncology trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03952767, a NA study of Oncology, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
63 participants
Enrollment target
1
Study location

Study Summary

This study assesses the association between digital functional measures of physical and patient-reported standard onocological assessments, like Karnofsky Performance Score (KPS).

Primary Outcome

At-home record of mean steps per day

Conditions Studied

Interventions

  • OTHER Digital Physical Measures and Survey Assessments

Study Locations (1)

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2019-04-24
Est. Completion 2022-08-30
Phase NA

What the finished NCT03952767 record still lists

NCT03952767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 525-participant average among 24 other Oncology trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Oncology appearing as the primary indexed condition, and to 1 intervention - of which Digital Physical Measures and Survey Assessments is the first listed.

NCT03952767 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT03952767 about?

NCT03952767 is a clinical study titled "The STEPP Study: Sensors To Evaluate Physical Performance". This study assesses the association between digital functional measures of physical and patient-reported standard onocological assessments, like Karnofsky Performance Score (KPS).

What is the current status of trial NCT03952767?

This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2019-04-24. Estimated completion is 2022-08-30.

What conditions does trial NCT03952767 study?

This clinical trial studies the following conditions: Oncology.

What interventions are being tested in trial NCT03952767?

The interventions under investigation include: Digital Physical Measures and Survey Assessments (OTHER).

Who is sponsoring clinical trial NCT03952767?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03952767 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Oncology

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03952767's enrollment target sits among peer trials

63 15th of 24 higher than 8 of 24 other Oncology trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Oncology trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03952767, the US trial registry maintained by the National Library of Medicine. NCT03952767 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.